- Home
- THAR
THAR
Tharimmune Inc.
as 07-26-2024 4:00pm EST
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 4.3M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 42.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -34.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.75 - $142.50 | Next Earning Date: | 08-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tharimmune Inc. (THAR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MILBY RANDY | THAR | CEO | Dec 15 '23 | Buy | $0.50 | 29,000 | $14,587.00 | 156,517 | SEC Form 4 |
| MILBY RANDY | THAR | CEO | Nov 30 '23 | Buy | $1.00 | 10,000 | $10,000.00 | 127,517 | SEC Form 4 |
Latest Tharimmune Inc. News
THAR Breaking Stock News: Dive into THAR Ticker-Specific Updates for Smart Investing
ACCESSWIRE
5 days ago
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
ACCESSWIRE
10 days ago
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
ACCESSWIRE
11 days ago
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
ACCESSWIRE
2 months ago
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
ACCESSWIRE
2 months ago
Tharimmune to Present at 2024 BIO International Convention
ACCESSWIRE
2 months ago
Tharimmune Announces 1-for-15 Reverse Stock Split
Newsfile
3 months ago
Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
ACCESSWIRE
3 months ago
Tharimmune To Participate in Two Upcoming Investor Conferences in May
Compare THAR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "THAR Tharimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.